The Challenge
Traditional KOL recruitment slowed critical decisions
For one global biopharma company, assessing the potential of a new cardioplegia solution meant starting from scratch in an unfamiliar therapeutic space. Their internal process for identifying Key Opinion Leaders (KOLs) was manual and fragmented, often taking 3 to 6 months.
Googling experts. Chasing publications. Cold outreach.
The process relied heavily on informal networks and personal referrals, with limited structure or documentation. Each new project required repeating this from the ground up, making it hard to move quickly on product opportunities.
The Solution
Expert access via a purpose-built primary research platform – powered by AI
By embedding Techspert into their research process, the biopharma company gained instant access to a streamlined, compliant way of engaging the right experts, fast.
Within just 24 hours of briefing, they received expert profiles tailored to their precise needs. From there, they rapidly connected with a focused group of eight specialists in cardioplegia, ranging from perfusionists to pediatric cardiothoracic surgeons, each screened for specific product experience.
All interviews, legal documentation, and call summaries were managed via Techspert’s AI-powered research platform, enabling faster workflows with fewer manual steps.
The Impact
Clearer consensus and a faster path to FDA submission
Instead of spending months gathering perspectives, the team reached alignment on the therapeutic landscape within weeks. They discovered there was no clear standard of care for cardioplegia. Most clinicians used their own formulations, often based on personal training. No gold-standard study yet existed.
Using insights from the calls, the company developed a robust study proposal and moved forward with FDA endorsement. A process that previously might have taken six months was now completed in a fraction of the time.
Internally, compliance teams also benefited. With documentation and fair market value agreements embedded into the platform, the legal approval process was reduced from weeks to 24 hours, marking a structural change that removed barriers and enabled faster scaling.
From research bottlenecks to business enablers
With Techspert now part of their toolkit, the company is applying the same model to new product assessments, especially in areas outside their current therapeutic focus. As their R&D and business development pipeline grows, they’re set up to make confident decisions faster, with insights they can trust, and workflows that scale.
Ready to see what the healthcare and life sciences primary research platform can do for you? Book your demo now.
